Evogene Ltd. (EVGN)Healthcare | Biotechnology | Rehovot, Israel | NasdaqCM
0.80 USD
-0.02
(-1.875%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.80 0.00 (0.000%) ⇩ (April 17, 2026, 4:54 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:49 p.m. EDT
EVGN is facing an existential Nasdaq compliance risk with a sub-$1.00 price threat looming by late September, while simultaneously suffering from deteriorating fundamentals including -80% revenue growth, negative cash flow, and a purely speculative trading range that contradicts the 'Strong Buy' analyst recommendation and recent volatility driven by AI news hype. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.105720 |
| AutoARIMA | 0.147104 |
| AutoETS | 0.150933 |
| MSTL | 0.166076 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.296 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.355 |
| Revenue per Share | 0.489 |
| Market Cap | 9,689,063 |
| Forward P/E | -1.00 |
| Beta | 0.95 |
| Profit Margins | -220.22% |
| Website | https://www.evogene.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.37007874 |
| Address1 | 13 Gad Feinstein Street |
| Address2 | Park Rehovot |
| All Time High | 203.9 |
| All Time Low | 0.72 |
| Ask | 1.01 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 58,570 |
| Average Daily Volume3 Month | 477,970 |
| Average Volume | 477,970 |
| Average Volume10Days | 58,570 |
| Beta | 0.953 |
| Bid | 0.5698 |
| Bid Size | 2 |
| Book Value | -0.009 |
| City | Rehovot |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8005 |
| Current Ratio | 4.539 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.8576 |
| Day Low | 0.7792 |
| Debt To Equity | 18.355 |
| Display Name | Evogene |
| Earnings Call Timestamp End | 1,772,719,200 |
| Earnings Call Timestamp Start | 1,772,719,200 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,779,366,600 |
| Earnings Timestamp Start | 1,779,366,600 |
| Ebitda | -13,264,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.695 |
| Enterprise To Revenue | 2.393 |
| Enterprise Value | 9,218,958 |
| Eps Current Year | -1.5 |
| Eps Forward | -0.8 |
| Eps Trailing Twelve Months | -1.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 946 6724 |
| Fifty Day Average | 0.8568 |
| Fifty Day Average Change | -0.056300044 |
| Fifty Day Average Change Percent | -0.065709665 |
| Fifty Two Week Change Percent | -37.007874 |
| Fifty Two Week High | 2.42 |
| Fifty Two Week High Change | -1.6195002 |
| Fifty Two Week High Change Percent | -0.6692149 |
| Fifty Two Week Low | 0.72 |
| Fifty Two Week Low Change | 0.08049995 |
| Fifty Two Week Low Change Percent | 0.111805476 |
| Fifty Two Week Range | 0.72 - 2.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,287,149,400,000 |
| Float Shares | 9,821,836 |
| Forward Eps | -0.8 |
| Forward P E | -1.0006249 |
| Free Cashflow | -17,494,624 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.06255 |
| Gross Profits | -241,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00962 |
| Held Percent Institutions | 0.02248 |
| Implied Shares Outstanding | 12,103,764 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,865,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel. |
| Long Name | Evogene Ltd. |
| Market | us_market |
| Market Cap | 9,689,063 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_3274115 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -14,157,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,871,168 |
| Number Of Analyst Opinions | 1 |
| Open | 0.783 |
| Operating Cashflow | -13,502,000 |
| Operating Margins | -15.81529 |
| Payout Ratio | 0.0 |
| Phone | 972 8 931 1900 |
| Post Market Change | -0.00049996376 |
| Post Market Change Percent | -0.062456436 |
| Post Market Price | 0.8 |
| Post Market Time | 1,776,459,297 |
| Previous Close | 0.8158 |
| Price Eps Current Year | -0.5336667 |
| Price Hint | 4 |
| Price To Book | -88.94444 |
| Price To Sales Trailing12 Months | 2.5146801 |
| Profit Margins | -2.20218 |
| Quick Ratio | 3.957 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0153000355 |
| Regular Market Change Percent | -1.8754641 |
| Regular Market Day High | 0.8576 |
| Regular Market Day Low | 0.7792 |
| Regular Market Day Range | 0.7792 - 0.8576 |
| Regular Market Open | 0.783 |
| Regular Market Previous Close | 0.8158 |
| Regular Market Price | 0.8005 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 66,558 |
| Return On Assets | -0.28768 |
| Return On Equity | -1.0069001 |
| Revenue Growth | -0.805 |
| Revenue Per Share | 0.489 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,103,764 |
| Shares Percent Shares Out | 0.0242 |
| Shares Short | 239,261 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 188,218 |
| Short Name | Evogene Ltd. |
| Short Percent Of Float | 0.0242 |
| Short Ratio | 1.32 |
| Source Interval | 15 |
| Symbol | EVGN |
| Target High Price | 2.25 |
| Target Low Price | 2.25 |
| Target Mean Price | 2.25 |
| Target Median Price | 2.25 |
| Total Cash | 12,956,000 |
| Total Cash Per Share | 1.31 |
| Total Debt | 2,198,000 |
| Total Revenue | 3,853,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.10855 |
| Two Hundred Day Average Change | -0.30804998 |
| Two Hundred Day Average Change Percent | -0.27788553 |
| Type Disp | Equity |
| Volume | 66,558 |
| Website | https://www.evogene.com |
| Zip | 7,638,517 |